Sue Goldie

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru
    Sue J Goldie
    Center for Health Decision Science, Harvard School of Public Health, Boston, MA, USA
    Rev Panam Salud Publica 32:426-34. 2012
  2. ncbi Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination
    Jeremy D Goldhaber-Fiebert
    Department of Health Policy and Management, Harvard School of Public Health, Boston, USA
    Popul Health Metr 5:11. 2007
  3. ncbi Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden
    Sun Young Kim
    Center for Health Decision Science, Harvard School of Public Health, Boston, MA, USA
    BMC Infect Dis 11:174. 2011
  4. ncbi Alternative strategies to reduce maternal mortality in India: a cost-effectiveness analysis
    Sue J Goldie
    Center for Health Decision Science, Harvard School of Public Health, Boston, Massachusetts, United States of America
    PLoS Med 7:e1000264. 2010
  5. ncbi Cost-effectiveness of cervical-cancer screening in five developing countries
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, Boston, USA
    N Engl J Med 353:2158-68. 2005
  6. ncbi Mathematical models of cervical cancer prevention in Latin America and the Caribbean
    Sue J Goldie
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Vaccine 26:L59-72. 2008
  7. ncbi Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Vaccine 24:S3/155-63. 2006
  8. ncbi Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparities
    Sue J Goldie
    Department of Health Policy and Management, Center for Health Decision Science, Harvard School of Public Health, Harvard Global Health Institute, Harvard University, 718 Huntington Ave, 2nd Floor, Boston, MA 02115, USA
    J Natl Cancer Inst 103:1373-86. 2011
  9. ncbi Mathematical models of cervical cancer prevention in the Asia Pacific region
    Sue J Goldie
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Vaccine 26:M17-29. 2008
  10. ncbi Chapter 19: Cost-effectiveness of cervical cancer screening
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Vaccine 24:S3/164-70. 2006

Detail Information

Publications89

  1. ncbi Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru
    Sue J Goldie
    Center for Health Decision Science, Harvard School of Public Health, Boston, MA, USA
    Rev Panam Salud Publica 32:426-34. 2012
    ..To estimate the benefits, cost-effectiveness (i.e., value for money), and required financial costs (e.g., affordability) of adding human papillomavirus (HPV) vaccination to Peru's cervical cancer screening program...
  2. ncbi Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination
    Jeremy D Goldhaber-Fiebert
    Department of Health Policy and Management, Harvard School of Public Health, Boston, USA
    Popul Health Metr 5:11. 2007
    ..S. policy choices for cervical cancer prevention, we developed a model of human papillomavirus (HPV) and cervical cancer, explicitly incorporating uncertainty about the natural history of disease...
  3. ncbi Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden
    Sun Young Kim
    Center for Health Decision Science, Harvard School of Public Health, Boston, MA, USA
    BMC Infect Dis 11:174. 2011
    ..The purpose of this study is to provide early insight into how the comparative impact of different new vaccines could be assessed in resource-poor settings with respect to affordability, cost-effectiveness, and distributional equity...
  4. ncbi Alternative strategies to reduce maternal mortality in India: a cost-effectiveness analysis
    Sue J Goldie
    Center for Health Decision Science, Harvard School of Public Health, Boston, Massachusetts, United States of America
    PLoS Med 7:e1000264. 2010
    ....
  5. ncbi Cost-effectiveness of cervical-cancer screening in five developing countries
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, Boston, USA
    N Engl J Med 353:2158-68. 2005
    ..Cervical-cancer screening strategies that involve the use of conventional cytology and require multiple visits have been impractical in developing countries...
  6. ncbi Mathematical models of cervical cancer prevention in Latin America and the Caribbean
    Sue J Goldie
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Vaccine 26:L59-72. 2008
    ..If the cost per vaccinated girl is less than I$25 HPV-16/18 vaccination would be very cost-effective in all 33 countries; for it to be affordable, costs may need to be lower...
  7. ncbi Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Vaccine 24:S3/155-63. 2006
    ....
  8. ncbi Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparities
    Sue J Goldie
    Department of Health Policy and Management, Center for Health Decision Science, Harvard School of Public Health, Harvard Global Health Institute, Harvard University, 718 Huntington Ave, 2nd Floor, Boston, MA 02115, USA
    J Natl Cancer Inst 103:1373-86. 2011
    ..However, models that also consider health disparities can identify strategies that improve both population health and its equitable distribution...
  9. ncbi Mathematical models of cervical cancer prevention in the Asia Pacific region
    Sue J Goldie
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Vaccine 26:M17-29. 2008
    ....
  10. ncbi Chapter 19: Cost-effectiveness of cervical cancer screening
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Vaccine 24:S3/164-70. 2006
    ..Despite differences in methods and assumptions, this paper identifies the qualitative themes that are consistent among studies, and highlights important methodological challenges and high-priority areas for further work...
  11. ncbi Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire
    Sue J Goldie
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, Boston, MA 02115, USA
    N Engl J Med 355:1141-53. 2006
    ..As antiretroviral therapy is increasingly used in settings with limited resources, key questions about the timing of treatment and use of diagnostic tests to guide clinical decisions must be addressed...
  12. ncbi A public health approach to cervical cancer control: considerations of screening and vaccination strategies
    Sue Goldie
    Department of Health Policy and Management, Program in Health Descision Science, Boston, MA 02115, USA
    Int J Gynaecol Obstet 94:S95-105. 2006
    ....
  13. ncbi When to start antiretroviral therapy in resource-limited settings
    Rochelle P Walensky
    Massachusetts General Hospital, Brigham and Women s Hospital, Harvard University Medical School, Harvard School of Public Health, and Boston University School of Public Health, Boston, Massachusetts 02114, USA
    Ann Intern Med 151:157-66. 2009
    ..The results of international clinical trials that are assessing when to initiate antiretroviral therapy (ART) will not be available for several years...
  14. ncbi Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance
    Jane J Kim
    Department of Health Policy and Management, Harvard Center for Risk Analysis, 718 Huntington Ave, Second Floor, Boston, MA 02115, USA
    JAMA 287:2382-90. 2002
    ..CONCLUSION: Reflex HPV DNA testing provides the same or greater life expectancy benefits and is more cost-effective than other management strategies for women diagnosed as having ASC-US...
  15. ncbi The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa
    Rochelle P Walensky
    Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 56:26-35. 2011
    ..Although 900,000 HIV-infected South Africans receive antiretroviral therapy, the majority of South Africans with HIV remain undiagnosed...
  16. ncbi Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness
    Felicitas C Kuehne
    Harvard Program on the Economic Evaluation of Medical Technology, 718 Huntington Ave, Second Floor, Boston, MA 02115-5924, USA
    Arch Intern Med 162:2545-56. 2002
    ..CONCLUSIONS: Combination therapy for moderate hepatitis in coinfected patients will increase quality-adjusted life expectancy and have a cost-effectiveness ratio comparable to that of other well-accepted clinical interventions...
  17. ncbi Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy
    Jane J Kim
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    J Natl Cancer Inst 97:888-95. 2005
    ..CONCLUSIONS: HPV DNA testing has the potential to improve health benefits at a reasonable cost compared with current screening policies in four European countries...
  18. ncbi Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults
    Bruce R Schackman
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Arch Intern Med 162:2478-86. 2002
    ....
  19. ncbi Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines
    Sue J Goldie
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Ave, Second Floor, Boston, MA 02115-5924, USA
    Arch Intern Med 162:921-8. 2002
    ..quot; In TMP/SMX-intolerant patients, dapsone is more cost-effective than atovaquone...
  20. ncbi The costs, benefits, and cost-effectiveness of interventions to reduce maternal morbidity and mortality in Mexico
    Delphine Hu
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, United States of America
    PLoS ONE 2:e750. 2007
    ..S. Although national efforts have been made to improve maternal services in the last decade, it is unclear if Millennium Development Goal 5--to reduce maternal mortality by three-quarters by 2015--will be met...
  21. ncbi Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States
    Jane J Kim
    Department of Health Policy and Management, Center for Health Decision Science, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Ann Intern Med 151:538-45. 2009
    ..The role of vaccination against HPV types 16 and 18, which is recommended routinely for preadolescent girls, is unclear in this age group...
  22. ncbi Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS
    Bruce R Schackman
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA
    Med Decis Making 22:27-38. 2002
    ....
  23. ncbi Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients
    April D Kimmel
    Division of General Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Antivir Ther 10:41-52. 2005
    ..Guidelines regarding the frequency of CD4 cell count and HIV RNA monitoring in HIV-infected patients vary, with recommended strategies ranging from every 2 to every 6 months...
  24. ncbi Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis
    Delphine Hu
    Harvard School of Public Health, Boston, Massachusetts 02115-5924, USA
    Ann Intern Med 141:501-13. 2004
    ..trachomatis screening for all women 15 to 29 years of age and selective targeting of those with a history of infection for semiannual screening is very cost-effective compared with other well-accepted clinical interventions...
  25. ncbi Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination
    Jeremy D Goldhaber-Fiebert
    Doctoral Program in Health Policy, Decision Science Concentration, Harvard University, Cambridge, MA, USA
    J Natl Cancer Inst 100:308-20. 2008
    ....
  26. ncbi HIV drug resistance surveillance for prioritizing treatment in resource-limited settings
    Rochelle P Walensky
    Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    AIDS 21:973-82. 2007
    ..Sentinel testing programs for HIV drug resistance in resource-limited settings can inform policy on antiretroviral therapy (ART) and drug sequencing...
  27. ncbi Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong
    Jane J Kim
    Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    J Public Health (Oxf) 26:130-7. 2004
    ..CONCLUSIONS: Compared with the status quo of opportunistic screening, adopting a policy of organized, mass cervical screening in Hong Kong can substantially increase benefits and reduce costs...
  28. ncbi Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal
    Elena Losina
    Division of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS Med 6:e1000173. 2009
    ..Our objective was to project the clinical impact and cost-effectiveness of interventions to prevent LTFU from HIV care in West Africa...
  29. ncbi Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients
    Kenneth A Freedberg
    Divisions of General Medicine and Infectious Diseases and the Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 43:S113-8. 2006
    ..Adherence interventions with modest effectiveness are likely to provide long-term survival benefit to patients and to be cost-effective compared with other uses of HIV care funds...
  30. ncbi Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves
    Sun Young Kim
    Program in Health Decision Science, Health Policy and Management Department, Harvard School of Public Health, Boston, MA 02115, USA
    Bull World Health Organ 85:833-42. 2007
    ..We sought to describe a method that explicitly considers both a health-care programmes cost-effectiveness and its affordability. For illustration, we apply the method to the programme to vaccinate infants against hepatitis B in the Gambia...
  31. ncbi Economic evaluation of pneumococcal conjugate vaccination in The Gambia
    Sun Young Kim
    Department of Health Policy and Management, Harvard School of Public Health, Center for Health Decision Science, Boston, MA, USA
    BMC Infect Dis 10:260. 2010
    ..Our objective was to assess the potential impact of PCVs of different valences in The Gambia...
  32. ncbi Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV
    Nicole G Campos
    Program in Health Policy, Harvard University, Cambridge, Mass, USA
    Am J Med 120:272-9. 2007
    ..Our objective was to use these data to examine the cost-effectiveness of treating HCV in an urban cohort of co-infected patients...
  33. ncbi Multiparameter calibration of a natural history model of cervical cancer
    Jane J Kim
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Epidemiol 166:137-50. 2007
    ..The authors found that leveraging primary data from longitudinal studies provides unique opportunities for model parameterization of the unobservable nature of HPV infection and its role in the development of cervical cancer...
  34. ncbi Health and economic implications of HPV vaccination in the United States
    Jane J Kim
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    N Engl J Med 359:821-32. 2008
    ..The cost-effectiveness of prophylactic vaccination against human papillomavirus types 16 (HPV-16) and 18 (HPV-18) is an important consideration for guidelines for immunization in the United States...
  35. ncbi Modeling cervical cancer prevention in developed countries
    Jane J Kim
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Vaccine 26:K76-86. 2008
    ..The objective of this review is to highlight points of consensus and qualitative themes, to discuss the areas of divergent findings, and to provide insight into critical decisions related to cervical cancer prevention...
  36. ncbi Effects of Helicobacter pylori infection and smoking on gastric cancer incidence in China: a population-level analysis of trends and projections
    Jennifer M Yeh
    Center for Health Decision Science, Harvard School of Public Health, 718 Huntington Avenue, 2nd Floor, Boston, MA 02115, USA
    Cancer Causes Control 20:2021-9. 2009
    ..Our aim was to (1) retrospectively estimate the effects of Helicobacter pylori (H. pylori) and smoking on past gastric cancer incidence and (2) project how interventions on these two risk factors can reduce future incidence...
  37. ncbi Exploring model uncertainty in economic evaluation of health interventions: the example of rotavirus vaccination in Vietnam
    Sun Young Kim
    Center for Health Decision Science, Harvard School of Public Health, Boston, MA, USA
    Med Decis Making 30:E1-E28. 2010
    ....
  38. ncbi Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer
    Jennifer M Yeh
    Center for Health Decision Science, Harvard School of Public Health, Boston, MA 02115, USA
    Cancer 116:2941-53. 2010
    ..The objective of this study was to estimate the clinical benefits and cost-effectiveness of treatment and endoscopic surveillance to prevent gastric cancer...
  39. ncbi Cost-effectiveness of Rotavirus vaccination in Vietnam
    Sun Young Kim
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    BMC Public Health 9:29. 2009
    ..g., the possibility of reinfection and varying degrees of partial immunity conferred by natural infection), and assess the influence of the features on the cost-effectiveness of rotavirus vaccination...
  40. ncbi Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Reprod Health Matters 16:86-96. 2008
    ..Concerns about financial costs and affordability highlight the need for lowering vaccine prices, cost-efficient mechanisms for delivery of vaccinations to adolescents, and creative sources of financing...
  41. ncbi Keeping the noise down: common random numbers for disease simulation modeling
    Natasha K Stout
    Program in Health Decision Science, Harvard School of Public Health, 718 Huntington Ave, Boston, MA 02115, USA
    Health Care Manag Sci 11:399-406. 2008
    ..We provide a tutorial introduction and demonstrate the application of common random numbers in an individual-level simulation model of the epidemiology of breast cancer...
  42. ncbi Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results
    Jennifer M Yeh
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, Boston, MA 02115, USA
    Int J Cancer 124:157-66. 2009
    ..These results illustrate the potential promise of a gastric cancer screening program and provide rationale for urgent clinical studies to move the prevention agenda forward...
  43. ncbi Trade-offs in cervical cancer prevention: balancing benefits and risks
    Natasha K Stout
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Ave, Second Floor, Boston, MA 02115, USA
    Arch Intern Med 168:1881-9. 2008
    ....
  44. ncbi Health and economic impact of rotavirus vaccination in GAVI-eligible countries
    Sun Young Kim
    Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    BMC Public Health 10:253. 2010
    ..Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries...
  45. ncbi Cost-effectiveness of rapid point-of-care prenatal syphilis screening in sub-Saharan Africa
    Chara E Rydzak
    MD PhD Program in Health Policy, Harvard Medical School, Boston, MA 02115, USA
    Sex Transm Dis 35:775-84. 2008
    ..We assess the cost-effectiveness of on-site prenatal syphilis screening with newly available rapid point-of-care screening tests in sub-Saharan Africa...
  46. ncbi Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy
    Jane J Kim
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Vaccine 26:4015-24. 2008
    ..e., <$5 per dose), and screening is offered at older ages...
  47. ncbi Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries
    Sue J Goldie
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Vaccine 26:4080-93. 2008
    ....
  48. ncbi Development of an empirically calibrated model of gastric cancer in two high-risk countries
    Jennifer M Yeh
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, 2nd Floor, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 17:1179-87. 2008
    ..As better data become available, the model can be refined and recalibrated, and, as such, be used as an iterative tool to assess the likely health and economic outcomes associated with gastric cancer prevention strategies...
  49. ncbi Scaling up antiretroviral therapy in South Africa: the impact of speed on survival
    Rochelle P Walensky
    The Divisions of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    J Infect Dis 197:1324-32. 2008
    ..Only 33% of eligible human immunodeficiency virus (HIV)-infected patients in South Africa receive antiretroviral therapy (ART). We sought to estimate the impact of alternative ART scale-up scenarios on patient outcomes from 2007-2012...
  50. ncbi A refined estimate of the average lifetime cost of pelvic inflammatory disease
    Jennifer M Yeh
    Department of Health Policy and Management, Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, 2nd Floor, Boston, MA 02115 5924, USA
    Sex Transm Dis 30:369-78. 2003
    ..The major complications of pelvic inflammatory disease (infertility, ectopic pregnancy, and chronic pelvic pain) are the leading cause of non-HIV sexually transmitted disease morbidity in the United States...
  51. ncbi Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease
    Paul E Sax
    Division of Infectious Disease and the Partners AIDS Research Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 39:69-77. 2005
    ..Because of the high cost of ENF compared with other antiretroviral agents, our objectives were to determine the potential long-term clinical impact and cost-effectiveness of ENF in these patients...
  52. ncbi Taking account of future technology in cost effectiveness analysis
    Joshua A Salomon
    Department of Population and International Health, Harvard School of Public Health, Harvard Center for Population and Development Studies, 9 Bow Street, Cambridge MA 02138, USA
    BMJ 329:733-6. 2004
  53. ncbi A potential error in evaluating cancer screening: a comparison of 2 approaches for modeling underlying disease progression
    Sue J Goldie
    Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115 5924, USA
    Med Decis Making 23:232-41. 2003
    ..Evaluating cancer screening often requires modeling the underlying disease process and not observed disease, particularly in the absence of direct evidence linking screening to a survival benefit...
  54. ncbi A therapeutic HIV vaccine: how good is good enough?
    Rochelle P Walensky
    Department of Medicine, Massachusetts General Hospital, and the Partners AIDS Research Center, Harvard Medical School, Boston, MA 02114, USA
    Vaccine 22:4044-53. 2004
    ..91 months (cost-effectiveness ratio US$ 45,500/QALY). Even modestly effective therapeutic HIV vaccines may produce small but meaningful increases in life expectancy and compare favorably to alternative uses of scarce HIV care resources...
  55. ncbi Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population
    Joshua A Salomon
    Harvard Center for Population and Development Studies, Cambridge, Mass 02138, USA
    JAMA 290:228-37. 2003
    ..Approximately 2.7 million US individuals are chronically infected with the hepatitis C virus (HCV). As public health campaigns are pursued, a growing number of treatment candidates are likely to have minimal evidence of liver damage...
  56. ncbi Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115 5924, USA
    J Natl Cancer Inst 96:604-15. 2004
    ..We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 vaccine in a population with an organized cervical cancer screening program...
  57. ncbi Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts 02115 5924, USA
    Obstet Gynecol 103:619-31. 2004
    ..To evaluate the cost-effectiveness of human papillomavirus (HPV) DNA testing as a primary screening test in combination with cervical cytology in women aged 30 years or more...
  58. ncbi Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection
    Sue J Goldie
    Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115 5924, USA
    Am J Med 115:632-41. 2003
    ..To explore the cost-effectiveness of interventions to improve adherence to combination antiretroviral therapy in patients with human immunodeficiency virus (HIV) infection...
  59. ncbi A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    Int J Cancer 106:896-904. 2003
    ..These include a better understanding of the heterogeneity of vaccine response, the effect of type-specific vaccination on other HPV types and the degree to which vaccination effect persists over time...
  60. ncbi Cost-effectiveness of HPV 16, 18 vaccination in Brazil
    Sue J Goldie
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, 718 Huntington Avenue, 2nd Floor, Boston, MA 02115, United States of America
    Vaccine 25:6257-70. 2007
    ....
  61. ncbi Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States
    Jane J Kim
    Harvard School of Public Health, Department of Health Policy and Management, Center for Health Decision Science, 718 Huntington Avenue, Boston, MA 02115, USA
    BMJ 339:b3884. 2009
    ..To assess the cost effectiveness of including preadolescent boys in a routine human papillomavirus (HPV) vaccination programme for preadolescent girls...
  62. ncbi The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality
    George R Seage
    Department of Epidemiology and Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Acquir Immune Defic Syndr 30:421-8. 2002
    ....
  63. ncbi Packaging health services when resources are limited: the example of a cervical cancer screening visit
    Jane J Kim
    Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, United States of America
    PLoS Med 3:e434. 2006
    ....
  64. ncbi The impact of natural history parameters on the cost-effectiveness of Chlamydia trachomatis screening strategies
    Delphine Hu
    Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts 02138, USA
    Sex Transm Dis 33:428-36. 2006
    ..To understand the potential impact of assumptions about the natural history of untreated Chlamydia trachomatis on the cost-effectiveness of screening strategies...
  65. ncbi Assessing the sensitivity of decision-analytic results to unobserved markers of risk: defining the effects of heterogeneity bias
    Karen M Kuntz
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    Med Decis Making 22:218-27. 2002
    ..This analysis provides a general framework to determine when issues of heterogeneity may be important...
  66. ncbi Health economics and cervical cancer prevention: a global perspective
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, 2nd floor Boston, MA 02115 5924, USA
    Virus Res 89:301-9. 2002
    ....
  67. ncbi The economic burden of noncervical human papillomavirus disease in the United States
    Delphine Hu
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Obstet Gynecol 198:500.e1-7. 2008
    ....
  68. ncbi Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis
    Paul E Sax
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Infect Dis 41:1316-23. 2005
    ..Our objective was to determine the clinical impact and cost-effectiveness of genotype resistance testing for treatment-naive patients with chronic HIV infection...
  69. ncbi Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy
    Rochelle P Walensky
    Division of Infectious Disease and the Partners AIDS Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    J Acquir Immune Defic Syndr 31:27-37. 2002
    ..These results can assist decision makers and those planning clinical trials in defining evidence-based performance measures for primary HIV infection treatment and future trials...
  70. ncbi The cost effectiveness of gonorrhea screening in urban emergency departments
    Julia E Aledort
    Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA
    Sex Transm Dis 32:425-36. 2005
    ..The prevalence of gonorrhea (GC) among adolescent and young women attending some urban emergency departments (EDs) ranges from 1% to 7%, but historically screening has not been logistically practical...
  71. ncbi When does quality-adjusting life-years matter in cost-effectiveness analysis?
    Richard H Chapman
    Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Health Econ 13:429-36. 2004
    ....
  72. ncbi Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes
    Geoffrey P Garnett
    Department of Infectious Disease Epidemiology, Imperial College London, St Mary s Campus, Norfolk Place, London, UK
    Vaccine 24:S3/178-86. 2006
    ..To date, model results are consistent in predicting a useful role for vaccine, but further epidemiological data are required to help test the validity of models...
  73. ncbi Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille, France
    Antivir Ther 7:257-66. 2002
    ..To estimate the treatment and health care costs of HIV infection or AIDS in France during the era of highly active antiretroviral therapy (HAART)...
  74. ncbi Assessing preferences for prevention versus treatment using willingness to pay
    Phaedra S Corso
    Harvard University School of Public Health, USA
    Med Decis Making 22:S92-101. 2002
    ..Information from opinion polls suggests citizens favor spending a higher proportion of all health care dollars on prevention rather than treatment...
  75. ncbi Empirically calibrated model of hepatitis C virus infection in the United States
    Joshua A Salomon
    Global Programme on Evidence for Health Policy, World Health Organization, Geneva, Switzerland
    Am J Epidemiol 156:761-73. 2002
    ..These findings have important implications both for individual clinical decisions and for broader public health policy...
  76. ncbi Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States
    David N Fisman
    City of Hamilton Social and Public Health Services Department, McMaster University, Hamilton, Ontario, Canada
    Sex Transm Dis 29:608-22. 2002
    ....
  77. ncbi State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards
    Mira Johri
    Department of Health Administration, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada
    Med Care 40:429-41. 2002
    ..The 54 state AIDS Drug Assistance Programs (ADAP) provide medications to HIV-infected persons with limited resources. Eligibility and coverage vary, raising concerns about health inequities...
  78. ncbi Introducing HPV vaccine in developing countries--key challenges and issues
    Jan M Agosti
    Global Health Program, Bill and Melinda Gates Foundation, Seattle, USA
    N Engl J Med 356:1908-10. 2007
  79. ncbi Economic evaluation of weight loss interventions in overweight and obese women
    Larissa Roux
    Department of Community Health Sciences, University of Calgary, Canada
    Obesity (Silver Spring) 14:1093-106. 2006
    ..To conduct a clinical and economic evaluation of outpatient weight loss strategies in overweight and obese adult U.S. women...
  80. ncbi Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille, France
    AIDS 19:1299-308. 2005
    ..In 2000, WHO/UNAIDS recommended co-trimoxazole prophylaxis for persons at early stages of HIV infection (WHO stage > or = 2) in sub-Saharan Africa...
  81. ncbi Cost-effectiveness analysis of treatment strategies for Stage I and II endometrial cancer
    Janice S Kwon
    Department of Obstetrics and Gynecology, University of Western Ontario, London
    J Obstet Gynaecol Can 29:131-9. 2007
    ..We evaluated the cost-effectiveness of two common strategies for managing early endometrial cancer as part of an Ontario population-based study...
  82. ncbi The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany
    Uwe Siebert
    Department of Public Health, Medical Decision Making and Health Technology Assessment, UMIT University of Health Sciences, Medical Informatics and Technology, Hall i T, Austria
    Eur J Public Health 16:185-92. 2006
    ..We sought to develop and validate a decision-analytic model for the natural history of cervical cancer for the German health care context and to apply it to cervical cancer screening...
  83. ncbi Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS)
    Shalini L Kulasingam
    Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA
    J Natl Cancer Inst 98:92-100. 2006
    ..We conducted a cost-effectiveness analysis of the ALTS trial to determine whether HPV DNA testing is a cost-effective alternative to immediate colposcopy or conservative management with up to three cytology examinations...
  84. ncbi Cost-effectiveness of alternative blood-screening strategies for West Nile Virus in the United States
    Caroline T Korves
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    PLoS Med 3:e21. 2006
    ..WNV can be transmitted by blood transfusion, and mandatory screening of blood for WNV was recently introduced throughout the US. Guidelines for selecting cost-effective strategies for screening blood for WNV do not exist...
  85. ncbi HPV communication: review of existing research and recommendations for patient education
    Rebecca Anhang
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    CA Cancer J Clin 54:248-59. 2004
    ....
  86. ncbi The cost-effectiveness of elective Cesarean delivery to prevent hepatitis C transmission in HIV-coinfected women
    Bruce R Schackman
    Divisions of Outcomes and Effectiveness, Department of Public Health, Weill Medical College of Cornell University, New York, NY 10021, USA
    AIDS 18:1827-34. 2004
    ....
  87. ncbi News media coverage of human papillomavirus
    Rebecca Anhang
    Harvard Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Suite 2, Boston, MA 02115-5924, USA
    Cancer 100:308-14. 2004
    ....
  88. ncbi Blood screening for west nile virus: the cost-effectiveness of a real-time, trigger-based strategy
    Caroline T Korves
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    Clin Infect Dis 43:490-3. 2006
    ..A newly proposed, real-time, trigger-based screening strategy was analyzed and was also shown to be not cost-effective. These results were highly sensitive to pricing of screening assays...
  89. ncbi Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment
    Bruce R Schackman
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Health Care Financ Rev 26:67-80. 2005
    ....